Skip to main content

Advertisement

SpringerLink
Log in

Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines  for the adjuvant treatment of early breast cancer?

  • Letter to the Editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Curigliano G, Criscitiello C (2017) Maximizing the clinical benefit of anthracyclines in addition to taxanes in the adjuvant treatment of early breast cancer. J Clin Oncol 35(23):2600–2603

    Article  PubMed  Google Scholar 

  2. Viale G, Regan MM, Mastropasqua MG, International Breast Cancer Study Group et al (2008) Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 100(3):207–212

    Article  CAS  PubMed  Google Scholar 

  3. Rocca A, Bravaccini S, Scarpi E et al (2014) Benefit from anthracyclines in relation to biological profiles in early breast cancer. Breast Cancer Res Treat 144(2):307–318

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola (FC), Italy

    Sara Bravaccini, Andrea Rocca & Giuseppe Bronte

Authors
  1. Sara Bravaccini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Rocca
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuseppe Bronte
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sara Bravaccini.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bravaccini, S., Rocca, A. & Bronte, G. Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines  for the adjuvant treatment of early breast cancer?. Breast Cancer Res Treat 168, 767–768 (2018). https://doi.org/10.1007/s10549-017-4630-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-017-4630-9

Search

Navigation